MainboardGMP
LIVE
LIVE GMP
MakeMyTrip (India) Ltd₹0·Sagar Defence Engineering Ltd₹0·Encube Ethicals Ltd₹0·Arjun Jewellers Ltd₹0·Atomberg Technologies Ltd₹0·GNI Infrastructure Ltd₹0·Punjab Carbonic Ltd₹0·Ratnadeep Retail Ltd.₹0·IFL Finance Ltd.₹0·J Pan Tubular Components Ltd₹0·MakeMyTrip (India) Ltd₹0·Sagar Defence Engineering Ltd₹0·Encube Ethicals Ltd₹0·Arjun Jewellers Ltd₹0·Atomberg Technologies Ltd₹0·GNI Infrastructure Ltd₹0·Punjab Carbonic Ltd₹0·Ratnadeep Retail Ltd.₹0·IFL Finance Ltd.₹0·J Pan Tubular Components Ltd₹0·
Home › IPOs › Onyx Biotec Ltd
ON
Onyx Biotec Ltd
CLOSED NSE SME Bookbuilding IPO Fresh Capital Onyx Biotec IPO GMP
GREY MARKET PREMIUM
₹ 0
No premium data
EST. LISTING PRICE
₹61
Issue Price: ₹ 61
Issue Price
₹61
Face Value
₹10
Lot Size
2,000 shares
Open Date
13 Nov 2024
Close Date
18 Nov 2024
Allotment
19 Nov 2024
Listing Date
22 Nov 2024
Exchange
NSE SME
Onyx Biotec IPO About the Company

Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company providing sterile water for injections. The company currently manufactures Sterile Water for Injections and serves as a pharmaceutical contract manufacturer, offering a comprehensive range of Dry Powder Injections and Dry Syrups for both the Indian and overseas markets.

The company has two manufacturing units in Solan, Himachal Pradesh. Unit I has a daily production capacity of 638,889 units of Sterile Water for Injections, while Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift.

The company clientele includes Hetero Healthcare Limited, Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Aristo Pharmaceuticals Private Limited, Macleods Pharmaceuticals Limited, Mapra Laboratories Private Limited, Axa Parenterals Limited, FDC Limited, Zuventus Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, Reliance Life Sciences Limited, among others.

As of May 31, 2024, the company had a client base of more than 100 Indian and multinational pharmaceutical companies.

The company has received certificates for the management system, ISO 9001:2015, and ISO 14001:2015 from ROHS Certification Private Limited.

As of July 31, 2024, the company has 175 employees across various departments.

...read more
Onyx Biotec IPO Objects of the Issue
Purpose Amount (₹ Cr)
Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use —
Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections; —
Prepayment or repayment of all or a portion of certain loans availed by the Company; and —
General Corporate Purposes. —
Onyx Biotec IPO Lead Managers
Horizon Management Pvt.Ltd
Financial Summary Amount in ₹ Lakhs
Metric 31 May 2024 31 Mar 2024 31 Mar 2023
Total Assets 7,477 7,414 5,872
Revenue 1,054 5,387 3,962
PAT 131 303 184
Net Worth 2,619 2,488 1,820
Reserves 1,286 1,156 1,230
Total Borrowing 3,156 3,078 2,923
Onyx Biotec IPO Key Financial Ratios
ROE
5
ROCE
4
RONW
5
PAT Margin
12
Debt/Equity
1
P/BV
3
Issue Details
Total Shares Offered
4,810,000 (100%)
Reserved for Market Maker
Up to ₹1 Cr
Net Offer to Public
Up to ₹28 Cr
Pre-Issue Shareholding
13,322,200 shares
Post-Issue Shareholding
18,132,200 shares
UPI Mandate
18 Nov 2024
IPO Analytics Dashboard
LIVE
Onyx Biotec IPO GMP Insights
👤
Retail Demand
Good
💼
HNI Interest
Good
🏦
QIB Demand
Strong
📊
Valuation
Strong
Onyx Biotec IPO GMP Strength Score
8 / 10 Good
0–3 Weak 3–6 Moderate 6–8 Good 8–10 Strong
Onyx Biotec IPO Category-wise Subscription Shares offered, bid & amount
Category Sub (x) Offered Bid For
🏦 QIB — 2,278,000 (47%) —
💼 NII / HNI — 688,000 (14%) —
👤 Retail (RII) — 1,600,000 (33%) —
📊 Market Maker — 244,000 (5%) —
Σ Total — 4,810,000 (100%) —

* Amount calculated at upper price band (₹61) ·  ** Total includes all investor categories

Subscription Overview Share allocation by investor category
🏦
QIB ? 2,278,000 (47%)
47%
💼
NII / HNI ? 688,000 (14%)
14%
👤
Retail (RII) ? 1,600,000 (33%)
33%
📊
Market Maker ? 244,000 (5%)
5%
Total Shares Offered 4,810,000 (100%)
Onyx Biotec IPO Application Sizing Minimum investment by category
👤 Retail Investors ?
Min. Lots 1
Shares / Lot 2,000
Min. Investment ₹122,000
💼 HNI Investors ?
Min. Lots 2
Min. Shares 4,000
Min. Investment ₹244,000
Onyx Biotec IPO Valuation — EPS & P/E Pre & post-issue metrics
Pre-Issue EPS ?
₹ 2
Post-Issue EPS ?
₹ 4
Pre-Issue P/E ?
27 x
Post-Issue P/E ?
14 x
Onyx Biotec IPO Timeline & Key Dates
  1. 1 💳 Initiation of Refund 20 Nov 2024
  2. 2 📂 Credit of Shares to Demat 20 Nov 2024
Investor Interpretation
  • Retail allocation is good at 33% of the total offering.
  • HNI/NII demand is good at 14%.
  • Institutional (QIB) interest is strong at 47%.
  • The IPO P/E of 14x reflects a strong valuation relative to typical market ranges.
  • Pre-issue EPS of ₹2 compares to post-issue EPS of ₹4 after dilution.

This IPO shows moderate investor interest. Review financial details and compare valuation with industry peers before investing.

STOCK PRICE HISTORY  ·  NSE
—
Issue Price: ₹ 61  ·  Symbol: —
H —
L —
O —
Onyx Biotec IPO Company Info
📍 Bir Plassi Near Sainimajraropar Nalagarh Road Solan, Himachal Pradesh, 174101
Visit Website
Onyx Biotec IPO Registrar
MAS Services Ltd.
Check Allotment Status
Onyx Biotec IPO FAQs
Onyx Biotec IPO has already listed. Its last recorded GMP was ₹0. GMP is only indicative and never a guarantee of listing gains.
The issue price of Onyx Biotec IPO is ₹61 per share. One lot has 2,000 shares, so the minimum investment is about ₹122,000. It is a Fresh Capital issue.
Onyx Biotec IPO opened on 13 Nov 2024 and closed on 18 Nov 2024. Allotment is tentatively finalised on 19 Nov 2024. Shares are listed on NSE SME on 22 Nov 2024.
Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company providing sterile water for injections. The company currently manufactures Sterile Water for Injections and serves as a pharmaceutical contract manufacturer, offering a comprehensive range of Dry Powder Inj…
As per the offer document, Onyx Biotec plans to use the IPO proceeds for: Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use; Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections;; Prepayment or repayment of all or a portion of certain loans availed by the Company; and; General Corporate Purposes..
The lead manager of Onyx Biotec IPO is Horizon Management Pvt.Ltd.
Onyx Biotec IPO is proposed to list on NSE SME; it is a Bookbuilding IPO and the issue is a Fresh Capital.
Disclaimer

The information on mainboardgmp.com is provided for educational and informational purposes only.

We are not a Securities and Exchange Board of India (SEBI)-registered investment advisor, analyst, broker, or financial planner. The content, data, and insights on this website, including Grey Market Premium (GMP), subscription data, IPO dates, and market information, are not intended as financial advice or recommendations to buy, sell, or hold securities.

GMP and related IPO data are collected from unofficial market sources and may not reflect actual IPO listing performance or future price movements. You should not rely solely on the information provided here to make financial or investment decisions.

Investing in IPOs and securities involves risk. Always conduct your own research and consult a qualified SEBI-registered financial advisor before making investment decisions. mainboardgmp.com and its owners shall not be liable for any financial losses, trading losses, or damages arising from use of this website.

By using this website, you acknowledge and agree that you use the content at your own risk.